Unusual Presentation of a Post-procedural Breast Hematoma: A Case Report.
Breast biopsy
Covid-19
case report
post-procedural hematoma
vacuum-assisted biopsy
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
08
05
2021
revised:
31
05
2021
accepted:
04
06
2021
entrez:
19
8
2021
pubmed:
20
8
2021
medline:
24
8
2021
Statut:
ppublish
Résumé
Hematoma is the most frequent complication after Vacuum-Assisted Breast Biopsy (VABB) in 13% of cases. A direct communication channel with patients eases the diagnosis of VABB complications and ensures treatment at an early stage, as outpatients, in most cases. In 2020, due to the COVID-19 pandemic, we observed a reduction of self-reported postoperative complication leading to delay in the identification of harmful complications, therefore leading to need for more invasive treatment. A 50-year-old patient was admitted to the Emergency Department for dry cough, fever, chest discomfort, dyspnea, and slight confusion four days after VABB. Due to the reported symptoms, the patient was sent to our COVID-19 Emergency Department. The COVID-19 swab was negative. Ultrasound revealed a large hematoma at the biopsy site, with active bleeding. Open evacuation with accurate hemostasis was planned with rapid and complete resolution of the clinical symptoms. After surgery, the patient reported that she intentionally avoided admittance in the hospital due to the risk of COVID-19 infection. The patient was discharged in the first postoperative day and maintained in quarantine for 14 days. In the COVID-19 era due to the risk of hospital cross-infections, reduction of patient-doctor communication could lead to misdiagnosis, delay in recognition of procedural complications thus leading to requirement for invasive treatment, hospitalization, while also further multiplying the risk of COVID-19 infection.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Hematoma is the most frequent complication after Vacuum-Assisted Breast Biopsy (VABB) in 13% of cases. A direct communication channel with patients eases the diagnosis of VABB complications and ensures treatment at an early stage, as outpatients, in most cases. In 2020, due to the COVID-19 pandemic, we observed a reduction of self-reported postoperative complication leading to delay in the identification of harmful complications, therefore leading to need for more invasive treatment.
CASE REPORT
METHODS
A 50-year-old patient was admitted to the Emergency Department for dry cough, fever, chest discomfort, dyspnea, and slight confusion four days after VABB. Due to the reported symptoms, the patient was sent to our COVID-19 Emergency Department. The COVID-19 swab was negative. Ultrasound revealed a large hematoma at the biopsy site, with active bleeding. Open evacuation with accurate hemostasis was planned with rapid and complete resolution of the clinical symptoms. After surgery, the patient reported that she intentionally avoided admittance in the hospital due to the risk of COVID-19 infection. The patient was discharged in the first postoperative day and maintained in quarantine for 14 days.
CONCLUSION
CONCLUSIONS
In the COVID-19 era due to the risk of hospital cross-infections, reduction of patient-doctor communication could lead to misdiagnosis, delay in recognition of procedural complications thus leading to requirement for invasive treatment, hospitalization, while also further multiplying the risk of COVID-19 infection.
Identifiants
pubmed: 34410994
pii: 35/5/2957
doi: 10.21873/invivo.12589
pmc: PMC8408686
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2957-2961Informations de copyright
Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Transplant Proc. 1998 Aug;30(5):1769-71
pubmed: 9723274
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cancer. 2010 Jun 15;116(12):2913-21
pubmed: 20336782
BMC Res Notes. 2010 Mar 12;3:70
pubmed: 20226029
Cochrane Database Syst Rev. 2020 Jun 2;6:CD007568
pubmed: 32483832
Onkologie. 2009 Jul;32(7):395-7
pubmed: 19556816
In Vivo. 2011 Jul-Aug;25(4):703-5
pubmed: 21709018
J Laparoendosc Adv Surg Tech A. 2020 Sep;30(9):1001-1007
pubmed: 32589496
Insights Imaging. 2020 Feb 5;11(1):12
pubmed: 32025985
In Vivo. 2017 01-02;31(1):101-110
pubmed: 28064227
Medicine (Baltimore). 2020 Mar;99(10):e19442
pubmed: 32150097
Anticancer Res. 2014 Jul;34(7):3831-7
pubmed: 24982410
Interact Cardiovasc Thorac Surg. 2010 May;10(5):704-8
pubmed: 20154347
Tumori. 2020 Apr;106(2):115-125
pubmed: 31451072
In Vivo. 2020 Jun;34(3 Suppl):1651-1659
pubmed: 32503825
In Vivo. 2020 Jun;34(3 Suppl):1685-1694
pubmed: 32503830
In Vivo. 2019 Nov-Dec;33(6):1879-1884
pubmed: 31662515
Ann Thorac Surg. 2010 Sep;90(3):973-8
pubmed: 20732526
World J Surg Oncol. 2008 May 19;6:51
pubmed: 18489771
PLoS One. 2017 Sep 18;12(9):e0184680
pubmed: 28922402
Cureus. 2020 Mar 30;12(3):e7479
pubmed: 32351857
Front Public Health. 2020 Dec 16;8:601748
pubmed: 33425839
Anticancer Res. 2020 Jan;40(1):281-286
pubmed: 31892577
AJR Am J Roentgenol. 2002 Sep;179(3):679-83
pubmed: 12185043
Anticancer Res. 1996 Jul-Aug;16(4B):2187-92
pubmed: 8694541
J Thorac Dis. 2015 Jul;7(7):1213-20
pubmed: 26380737
JAMA. 2019 Jan 22;321(3):288-300
pubmed: 30667505
In Vivo. 2020 Sep-Oct;34(5):3033-3038
pubmed: 32871849
Anticancer Res. 2018 Apr;38(4):2109-2117
pubmed: 29599329
Anticancer Res. 2021 Jan;41(1):307-316
pubmed: 33419825
Anticancer Res. 2001 May-Jun;21(3C):2091-7
pubmed: 11501831
Int J Surg. 2010;8(5):353-5
pubmed: 20438874
Eur J Radiol. 2012 May;81(5):e739-45
pubmed: 22381441
Tumori. 2002 May-Jun;88(3):S48-9
pubmed: 12365390
Acta Radiol. 2008 Sep;49(7):752-4
pubmed: 19143060